Literature DB >> 26905919

Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.

Hsing-Chang Ni1, Shoou-Lian Hwang Gu2, Hsiang-Yuan Lin3, Yu-Ju Lin4, Li-Kuang Yang5, Hui-Chun Huang6, Susan Shur-Fen Gau7.   

Abstract

OBJECTIVE: Intra-individual variability in reaction time (IIV-RT) is common in individuals with attention-deficit/hyperactivity disorder (ADHD). It can be improved by stimulants. However, the effects of atomoxetine on IIV-RT are inconclusive. We aimed to investigate the effects of atomoxetine on IIV-RT, and directly compared its efficacy with methylphenidate in adults with ADHD.
METHODS: An 8-10 week, open-label, head-to-head, randomized clinical trial was conducted in 52 drug-naïve adults with ADHD, who were randomly assigned to two treatment groups: immediate-release methylphenidate (n=26) thrice daily (10-20 mg per dose) and atomoxetine once daily (n=26) (0.5-1.2 mg/kg/day). IIV-RT, derived from the Conners' continuous performance test (CCPT), was represented by the Gaussian (reaction time standard error, RTSE) and ex-Gaussian models (sigma and tau). Other neuropsychological functions, including response errors and mean of reaction time, were also measured. Participants received CCPT assessments at baseline and week 8-10 (60.4±6.3 days).
RESULTS: We found comparable improvements in performances of CCPT between the immediate-release methylphenidate- and atomoxetine-treated groups. Both medications significantly improved IIV-RT in terms of reducing tau values with comparable efficacy. In addition, both medications significantly improved inhibitory control by reducing commission errors.
CONCLUSION: Our results provide evidence to support that atomoxetine could improve IIV-RT and inhibitory control, of comparable efficacy with immediate-release methylphenidate, in drug-naïve adults with ADHD. Shared and unique mechanisms underpinning these medication effects on IIV-RT awaits further investigation.
© The Author(s) 2016.

Entities:  

Keywords:  Adult; atomoxetine; attention-deficit/hyperactivity disorder; ex-Gaussian distribution; intra-individual variability in reaction time; methylphenidate

Mesh:

Substances:

Year:  2016        PMID: 26905919     DOI: 10.1177/0269881116632377

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

1.  The use of reaction time distributions to study attention in male rats: the effects of atomoxetine and guanfacine.

Authors:  Zach V Redding; Pooja Chawla; Karen E Sabol
Journal:  Psychopharmacology (Berl)       Date:  2019-07-18       Impact factor: 4.530

2.  Neural correlates of atomoxetine improving inhibitory control and visual processing in Drug-naïve adults with attention-deficit/hyperactivity disorder.

Authors:  Li-Ying Fan; Tai-Li Chou; Susan Shur-Fen Gau
Journal:  Hum Brain Mapp       Date:  2017-06-28       Impact factor: 5.038

Review 3.  Current Pharmacological Treatments for ADHD.

Authors:  Madeleine J Groom; Samuele Cortese
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 4.  Linking ADHD to the Neural Circuitry of Attention.

Authors:  Adrienne Mueller; David S Hong; Steven Shepard; Tirin Moore
Journal:  Trends Cogn Sci       Date:  2017-05-05       Impact factor: 20.229

5.  Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Raissa Carolina F Cândido; Cristiane A Menezes de Padua; Su Golder; Daniela R Junqueira
Journal:  Cochrane Database Syst Rev       Date:  2021-01-18

6.  Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment.

Authors:  Ann-Marie Low; Julijana le Sommer; Signe Vangkilde; Birgitte Fagerlund; Birte Glenthøj; Edmund Sonuga-Barke; Thomas Habekost; Jens Richardt Møllegaard Jepsen
Journal:  Int J Neuropsychopharmacol       Date:  2018-11-01       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.